Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all trans-retinoic acid and cytotoxic treatment

Leukemia Research

Volumn 27, Issue 8, 2003, Pages 731-738

  Grčević, Danka ^a   Marušić, Ana ^a   Grahovac, Blaženka ^b   Jakšić, Branimir ^c   Kušec, Rajko ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b CROATIAN INSTITUTE OF TRANSFUSION MEDICINE   (Croatia)

^c University of Zagreb   (Croatia)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Bone marrow cells; Bone morphogenetic proteins; Fusion gene PML RAR ; Gene expression

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR; CYTOTOXIC AGENT; IDARUBICIN; MESSENGER RNA; OSTEOGENIC PROTEIN 1; RETINOIC ACID; TUMOR MARKER;

ADULT; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUSION GENE; HUMAN; HUMAN TISSUE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, GROWTH FACTOR; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRETINOIN;

EID: 0037866462     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00281-3     Document Type: Article

References (44)

1. Douer D. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol. 107:2002;1-17.
2. Warrell R.P. Jr., de The H., Wang Z.Y., Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 329:1993;177-189.
3. Lallemand-Breitenbach V., Guillemin M.-C., Janin A., Daniel M.-T., Degos L., Kogan S.C.et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1999;1043-1052.
4. Mann K.K., Shao W., Miller W.H. Jr. The biology of acute promyelocytic leukemia. Curr. Oncol. Rep. 3:2001;209-216.
5. Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T.et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 56:1996;2945-2948.
6. Glozak M.A., Rogers M.B. BMP-4 and RA-induced apoptosis is mediated through the activation of retinoic acid receptor α and γ in P19 embryonal carcinoma cells. Exp. Cell Res. 242:1998;165-173.
7. Rogers M.B., Rosen V., Wozney J.M., Gudas L.J. Bone morphogenetic proteins-2 and -4 are involved in the retinoic acid-induced differentiation of embryonal carcinoma cells. Mol. Biol. Cell. 3:1992;189-1196.
8. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W.et al. Novel regulators of bone formation: molecular clones and activities. Science. 242:1988;1528-1534.
9. Hogan B.L. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 10:1996;1580-1594.
10. Whitman M. Smads and early developmental signaling by the TGF-β superfamily. Genes Dev. 12:1998;2445-2462.
11. Kawamura C., Kizaki M., Yamato K., Uchida H., Fukuchi Y., Hattori Y.et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood. 96:2000;2005-2011.
12. Detmer K., Steele T.A., Shoop M.A., Dannawi H. Lineage-restricted expression of bone morphogenetic protein genes in human hematopoietic cell lines. Blood Cells Mol. Dis. 25:1999;310-323.
13. Marušić A., Katavić V., Grčević D. New bone induction by bone matrix and recombinant human bone morphogenetic protein-2 in the mouse. Croat. Med. J. 37:1996;237-244.
14. Ishisaki A., Yamato K., Hashimoto S., Nakao A., Tamaki K., Nonaka K.et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J. Biol. Chem. 274:1999;13637-13642.
15. Maeno M., Mead P.E., Kelley C., Xu R.H., Kung H.F., Suzuki A.et al. The role of BMP-4 and GATA-2 in the induction and differentiation of hematopoietic mesoderm in Xenopus laevis. Blood. 88:1996;1965-1972.
16. Johansson B.M., Wiles M.V. Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. Mol. Cell Biol. 15:1995;141-151.
17. Gilboa L., Nohe A., Geissendörfer T., Sebald W., Henis Y.I., Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol. Biol. Cell. 11:2000;1023-1035.
18. Derynck R., Zhang Y., Feng X.-H. Smads: transcriptional activators of TGF-β responses. Cell. 95:1998;737-740.
19. Bhatia M., Bonnet D., Wu D., Murdock B., Wrana J., Gallacher L.et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J. Exp. Med. 189:1999;1139-1147.
20. Chen D., Ji X., Harris M.A., Feng J.Q., Karsenty G., Celeste A.J.et al. Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J. Cell Biol. 142:1998;295-305.
21. 2. J. Cell. Physiol. 190:2002;207-217.
22. Glozak M.A., Rogers M.B. Specific induction of apoptosis in P19 embryonal carcinoma cells by retinoic acid and BMP2 or BMP4. Dev. Biol. 179:1996;458-470.
23. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D.et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813-819.
24. Chromczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
25. Grčević D., Lee S.-K., Marušić A., Lorenzo J.A. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J. Immunol. 165:2000;4231-4238.
26. Barragán E., Bolufer P., Martín G., Cervera J., Moreno I., Capote F.J.et al. Identification of two atypical PML-RARα transcripts in two patients with acute promyelocytic leukemia. Leuk. Res. 26:2002;439-442.
27. van Dongen J.J.M., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G.et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 13:1999;1901-1928.
28. Bentley H., Hamdy F.C., Hart K.A., Seid J.M., Williams J.L., Johnstone D., Russell R.G. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer. 66:1992;1159-1163.
29. Bijl J., van Oostveen J.W., Kreike M., Rieger E., van der Raaij-Helmer L.M.H., Walboomers J.M.M.et al. Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue. Blood. 87:1996;1737-1745.
30. Marušić A., Grčević D., Katavić V., Ksovačić N., Lukić I.K., Kalajzić I., Lorenzo J.A. Role of B lymphocytes in new bone formation. Lab. Invest. 80:2000;1761-1774.
31. Helvering L.M., Sharp R.L., Ou X., Geiser A.G. Regulation of the promoters for the human bone morphogenetic protein 2 and 4 genes. Gene. 256:2000;123-138.
32. Heller L.C., Li Y., Abrams K.L., Rogers M.B. Transcriptional regulation of the Bmp2 gene. Retinoic acid induction in F9 embryonal carcinoma cells and Saccharomyces cerevisiae. J. Biol. Chem. 274:1999;1394-1400.
33. Edwards R.H., Wasik M.A., Finan J., Rodriguez R., Moore J., Kamoun M.et al. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. Am. J. Clin. Pathol. 112:1999;819-827.
34. Bartsch D., Hahn S.A., Danichevski K.D., Ramaswamy A., Bastian D., Galehdari H.et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene. 18:1999;2367-2371.
35. Hahn S.A., Bartsch D., Schroers A., Galehdari H., Becker M., Ramaswamy A.et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 58:1998;1124-1126.
36. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J.et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 13:1996;343-346.
37. Miyamoto H., Kubota Y., Shuin T., Torigoe S., Dobashi Y., Hosaka M. Expression of transforming growth factor-β1 in human bladder cancer. Cancer. 75:1995;2565-2570.
38. Murray P.A., Barrett-Lee P., Travers M., Luqmani Y., Powles T., Coombes R.C. The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer. 67:1993;1402-1412.
39. Yamada N., Kato M., ten Dijke P., Yamashita H., Sampath T.K., Heldin C.H.et al. Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. Br. J. Cancer. 73:1996;624-629.
40. Church V.L., Harvey B., Ashton B.A. Differential bone morphogenetic protein expression by pluripotent bone marrow stromal stem cells. Biochem. Soc. Trans. 26:1998;S25.
41. Caricasole A., Ward-van Oostwaard D., Zeinstra L., van den Eijnden-van Raaij A., Mummery C. Bone morphogenetic proteins (BMPs) induce epithelial differentiation of NT2D1 human embryonal carcinoma cells. Int. J. Dev. Biol. 44:2000;443-450.
42. Weston A.D., Rosen V., Chandraratna R.A.S., Underhill T.M. Regulation of skeletal progenitor differentiation by the BMP and retinoid signaling pathways. J. Cell Biol. 148:2000;679-690.
43. Glozak M.A., Rogers M.B. Retinoic acid- and bone morphogenetic protein 4-induced apoptosis in P19 embryonal carcinoma cells requires p27. Exp. Cell Res. 268:2001;128-138.
44. Lee S.-H., Fu K.K., Hui J.N., Richman J.M. Noggin and retinoic acid transform the identity of avian facial prominences. Nature. 414:2001;909-912.